Cardiva Medical Acquisition, Valuation, Funding & Investors

SmartCella is a Milan-based biotechnology company advancing cell therapy delivery for cardiac regeneration. Its SmartCella device enables precise intracoronary injection of stem cells, drugs, and RNA therapeutics during procedures. Tested in preclinical models for heart failure and myocardial infarction, it partners with clinics in Italy and the EU. Founded in 2016, SmartCella focuses on interventional cardiology applications.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Medrobotics is a medical robotics firm commercializing the Flex Robotic System, a steerable and shapeable endoscopic platform. The system enables minimally invasive access to complex anatomies like the throat, lung, and prostate through a single small incision, surpassing rigid tool limitations.

Strand Therapeutics is a Cambridge-headquartered biotechnology firm founded in 2017 that engineers programmable mRNA medicines using synthetic biology principles. The platform deploys logic circuits within cells to detect tumor-specific signals and produce cancer-fighting proteins on demand, such as cytokines for immunotherapy. Their lead candidates target solid tumors including glioblastoma and head-and-neck cancers through intravenous administration. Strand Therapeutics collaborates with academic institutions like MIT and has progressed multiple programs into preclinical testing for oncology applications.

Ring Therapeutics is a biotechnology company developing Anellovector gene therapies derived from human commensal viruses for redosable and targeted treatments. Backed by Flagship Pioneering and based in Cambridge, Massachusetts, it advances platforms beyond traditional gene replacement for diseases like liver disorders and muscle wasting. Founded in 2022, Ring Therapeutics pioneers viral vectors for immunology and oncology applications.

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Precision Neuroscience is a New York-headquartered developer of brain-computer interface technology. Founded in 2021, it creates minimally invasive, removable cortical implants capable of high-resolution neural recording to treat neurological disorders affecting billions globally.

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Shoreline Biosciences is a biotechnology company developing allogeneic, off-the-shelf cellular immunotherapies for cancer, using induced pluripotent stem cells (iPSCs) to derive natural killer cell and macrophage therapies for solid tumors and blood cancers. Founded in 2020 by Kleanthis Xanthopoulos and based in San Diego, the company builds smart manufacturing capabilities to support its pipeline and holds strategic partnerships with Kite, a Gilead company, and BeiGene for cell therapy development.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kai Medtech markets and sells vascular intervention medical devices with a focus on nerve intervention entry points. Shanghai-headquartered, the company maintains a research-production-marketing closed-loop system to advance technology in endovascular treatments across China and Asia.

Ollin Biosciences is an Austin, Texas-based clinical-stage biopharmaceutical company that acquires and develops bispecific antibody therapies for vision-threatening eye diseases rather than pursuing in-house drug discovery. Its lead candidate, OLN324, is a VEGF/Ang2 bispecific antibody licensed from China's Innovent Biologics that is advancing toward Phase 3 trials for diabetic macular edema and wet age-related macular degeneration. A second program, OLN102, licensed from VelaVigo, is a TSHR/IGF-1R bispecific antibody in development for thyroid eye disease and Graves' disease.

Expedition Therapeutics is a San Diego-headquartered clinical-stage biotech developing oral therapies for inflammatory respiratory diseases. Its lead candidate, EXPD-101, inhibits dipeptidyl peptidase 1 to reduce neutrophilic inflammation in chronic obstructive pulmonary disease and bronchiectasis. The company completed Phase 1 trials in 2023 and plans Phase 2 studies in 2024 across Europe and North America. Expedition in-licenses assets while building internal pipelines, supported by a team from GSK and AstraZeneca. It operates R&D facilities in La Jolla, California.

Galvanize Therapeutics is a Boston-headquartered medical device company developing pulsed field ablation platforms for respiratory, cardiac, and oncology applications. Its portfolio features the Galaxy system for bronchoscopic lung volume reduction in chronic obstructive pulmonary disease patients and the Pulse Field Ablation platform for atrial fibrillation. The company targets solid tumors through non-thermal tissue ablation and holds FDA Breakthrough Device Designation for its cardiac rhythm management tools. Backed by Apple Tree Partners since its 2022 inception, Galvanize Therapeutics advances therapies across U.S. clinical sites and international partnerships.

SetPoint Medical is a Los Angeles-based medical device company developing the SetPoint System, an implantable vagus nerve stimulator for treating rheumatoid arthritis in adults unresponsive to conventional therapies. The wireless device modulates inflammation via bioelectronic signals. SetPoint Medical advances clinical trials in the United States and Europe for autoimmune indications.

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Direct Biologics is an Austin-based developer and cGMP manufacturer of regenerative biologics derived from human amniotic tissue and umbilical cord sources. The company produces products like EmD (extracellular microenvironment dressing) for wound care and DBM (decellularized bone matrix) for orthopedic applications. As a leader in the biologics space, Direct Biologics supplies hospitals, surgery centers, and clinics with shelf-stable allografts that promote tissue repair and reduce inflammation. Operating FDA-registered facilities, the firm adheres to stringent quality standards for clinical use in sports medicine, spine surgery, and general orthopedics across the United States.